Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans

Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Humans

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01331382

Enrollment

Registered

2011-04-08

Start date

2010-04-30

Completion date

2010-11-30

Last updated

2011-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Resveratrol, Piperine, Cerebral blood flow, Near- infrared spectroscopy, Bioavailability

Brief summary

Resveratrol is associated with a plethora of physiological effects in humans, including modulation of cerebral blood flow, despite apparently poor bioavailability. This study investigated whether the physiological effects of resveratrol could be affected when co-supplemented with piperine, an alkaloid which may be able to enhance the bioavailability of resveratrol.

Interventions

DIETARY_SUPPLEMENTTrans- resveratrol

All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

OTHERPlacebo (silica)

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Between the ages of 18-35 years old * Healthy * Non-smoker

Exclusion criteria

* Not proficient in English * Taking medication or herbal supplements * Pregnant or breast feeding * Heavy caffeine consumer * History of head trauma, migraines, learning difficulties, ADHD, gastrointestinal problems. * Food allergies of intolerances

Design outcomes

Primary

Measure	Time frame
Modulation of levels of oxygenated haemoglobin	80 minutes following treatment administration
Modulation of levels of deoxygenated haemoglobin	80 minutes following treatment administration
Modulation of levels of total haemoglobin	80 minutes following treatment administration

Secondary

Measure	Time frame	Description
Number of participants displaying significant modulation of cognitive performance	40-80 minutes post dose	Cognitive performance was assessed at baseline and then again 40 minutes post-treatment to assess if any changes had taken place.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026